Physician profile
Alison Badders
NPI 1447898739
$2,314.00
in general payments reported to CMS, 2019-2025
24 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $533 · 2023: $405 · 2024: $164 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $369.92 | 2021 | |
| Mayne Pharma Commercial LLC | $359.50 | 2022-2025 | |
| Novo Nordisk INC | $297.46 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Hologic Sales and Service, LLC | $274.97 | 2022-2025 | Acessa Provu System, Thinprep 2000 Processor, Aptima |
| Astellas Pharma US INC | $131.50 | 2023-2025 | Veozah |
| Abbvie INC. | $120.16 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $108.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $100.00 | 2021 | |
| Pfizer INC. | $85.37 | 2021-2023 | |
| Organon LLC | $52.79 | 2022-2025 | Nexplanon |
| Exeltis, USA INC. | $45.92 | 2022-2023 | Slynd |
| Amgen INC. | $44.37 | 2021 | |
| Lilly USA, LLC | $41.00 | 2021 | |
| Millicent US INC | $39.95 | 2024-2025 | Intrarosa, Femlyv |
| Agile Therapeutics, INC. | $29.30 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $28.94 | 2022 | |
| Clarus Therapeutics INC. | $28.55 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $26.47 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.41 | 2022 | |
| Genentech USA, INC. | $23.94 | 2021 | |
| Radius Health, INC. | $23.54 | 2024 | Tymlos |
| Therapeuticsmd, INC. | $20.90 | 2022 | |
| Evofem Biosciences, INC. | $18.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Badders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.